Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341625 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
NCT02341625: Clinical Trial Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT02341625 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 126 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (110% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02341625, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986148 administered alone and in combination with nivolumab in patients with mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer and gastric cancer.
Primary Outcome
Number of participants with adverse events at worst CTC grade including any grade adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuations, and deaths grouped by dose + dose regimen.
Interventions
- BIOLOGICAL Nivolumab
- DRUG BMS-986148
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2015-06-19 |
| Est. Completion | 2020-05-07 |
| Phase | Phase 1 |
Why NCT02341625 stopped before completion
NCT02341625 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (110% higher).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02341625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02341625 about?
NCT02341625 is a clinical study titled "A Study of BMS-986148 in Patients With Select Advanced Solid Tumors". The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986148 administered alone and in combination with nivolumab in patients with mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cance...
What is the current status of trial NCT02341625?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2015-06-19. Estimated completion is 2020-05-07.
What interventions are being tested in trial NCT02341625?
The interventions under investigation include: Nivolumab (BIOLOGICAL), BMS-986148 (DRUG).
Who is sponsoring clinical trial NCT02341625?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02341625's enrollment target sits among peer trials
126 461st of 2000 higher than 1,534 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI